• Ian M Adcock, Surya P Bhatt, Ronald Balkissoon, and Robert A Wise.
• National Heart & Lung Institute, Imperial College London, United Kingdom. Electronic address: ian.adcock@imperial.ac.uk.
• Am. J. Med. 2022 Mar 1; 135 (3): 302-312.

AbstractThe use of inhaled corticosteroids (ICS) in combination with inhaled bronchodilators for patients with chronic obstructive pulmonary disease (COPD) is a common practice in primary care settings. However, ICS-containing therapies may be less effective in patients with COPD compared with asthma, and in individuals with COPD who continue to smoke cigarettes. Preclinical studies suggest that inflammation in COPD is very different from in asthma. Glucocorticoid receptor functioning and other innate anti-inflammatory mechanisms are altered in cells exposed to cigarette smoke. COPD may be relatively insensitive to ICS, especially in individuals who continue to smoke. ICS-containing therapies in patients with asthma who continue to smoke may also be less effective compared with patients who do not smoke. ICS-containing therapies may be inappropriately used in some patients with COPD, and their long-term use is associated with an increased risk for side effects, including pneumonia and bone fractures in some patients. Treatment for patients with COPD should be carefully evaluated, and anti-inflammatory/bronchodilatory strategies should be chosen based on individual patient characteristics and recommendations in current guidelines.Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

24 keywords...

hide…